Utilization of gene-engineered T cells for enhancing cancer immunotherapy

利用基因工程 T 细胞增强癌症免疫治疗

• 批准号: nhmrc : 1041828
• 负责人: A/Pr Phillip Darcy
• 金额: $ 50.79万
• 依托单位: The University of Melbourne
• 依托单位国家: 澳大利亚
• 项目类别: Research Fellowships
• 财政年份: 2013
• 资助国家: 澳大利亚
• 起止时间: 2013-01-01 至 2017-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/utilization-gene-engineered-cancer-immunotherapy/111397
• 关键词: Utilization; gene; engineered; cells; enhancing

Killer T lymphocytes can penetrate tumours and their transfer into cancer patients has demonstrated some encouraging results, but this form of therapy and other approaches including vaccination remain ineffective in most cancer patients. In this project, we propose to improve the tumour trafficking and anti-tumour activities of killer cells by genetically engineering them with proteins that will enable them to recognise and destroy cancer cells, whilst minimizing toxicity to normal tissue.

杀伤性T淋巴细胞可以穿透肿瘤，它们转移到癌症患者体内已经证明了一些令人鼓舞的结果，但这种形式的治疗和其他方法，包括疫苗接种，在大多数癌症患者中仍然无效。在这个项目中，我们建议通过用蛋白质对杀伤细胞进行基因工程改造，使它们能够识别和摧毁癌细胞，同时最大限度地减少对正常组织的毒性，来改善杀伤细胞的肿瘤运输和抗肿瘤活性。